Details of Disease

General Information of Disease (ID: DISBIPKM)

• Disease Name: Kidney cancer
• Synonyms: malignant tumour of the kidney; malignant tumour of kidney; malignant tumor of the kidney; malignant tumor of kidney; malignant renal tumour; malignant renal tumor; malignant renal neoplasm; malignant neoplasm of the kidney; malignant neoplasm of kidney except pelvis; malignant neoplasm of kidney; malignant kidney tumour; malignant kidney tumor; malignant kidney neoplasm; kidney cancer; cancer of kidney
• Disease Class: 2C90: Renal cell carcinoma
• Definition: Primary or metastatic malignant neoplasm involving the kidney.
• Disease Hierarchy:
  DISAT1Z9: Advanced cancer
  DISDQ6PK: Malignant urinary system neoplasm
  DISBNZTN: Kidney neoplasm
  DISBIPKM: Kidney cancer
• ICD Code:
  ICD-11: ICD-11: 2C90.0
  ICD-9: ICD-9: 189
  Expand ICD-9: 189
• Disease Identifiers:
  MONDO ID: MONDO_0002367
  MESH ID: D007680
  UMLS CUI: C0740457
  MedGen ID: 149263
  SNOMED CT ID: 363518003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Everolimus	DM8X2EH	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Biomed 101	DMQ9KZW	Phase 1	Small molecular drug	[2]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Geldanamycin	DMS7TC5	Discontinued in Phase 2	Small molecular drug	[3]
Dendritic cell PEG fusion cancer vaccine	DMVNRW7	Discontinued in Phase 1/2	NA	[4]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 78 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCB1	TT3OT40	Limited	Biomarker	[5]
AMACR	TTLN1AP	Limited	Altered Expression	[6]
ATP1A1	TTWK8D0	Limited	Biomarker	[7]
CDH6	TT9QHUK	Limited	Altered Expression	[8]
COPS5	TTSTNJR	Limited	Biomarker	[9]
DKK3	TTY2ZV6	Limited	Biomarker	[10]
IL16	TTW4R0B	Limited	Genetic Variation	[11]
KDM3A	TTKXS4A	Limited	Altered Expression	[12]
KDM6B	TTDIJUQ	Limited	Biomarker	[13]
MCAM	TTHRE05	Limited	Biomarker	[14]
SLC16A3	TTG6VD5	Limited	Biomarker	[15]
SLC5A5	TTW7HI9	Limited	Therapeutic	[16]
ACO2	TTMTF2P	moderate	Genetic Variation	[17]
CA9	TT2LVK8	moderate	Biomarker	[18]
CRY2	TTAO58M	moderate	Altered Expression	[19]
F12	TTRJSMV	moderate	Altered Expression	[20]
KIF11	TTBGTCW	moderate	Biomarker	[21]
MMP16	TTNP4CU	moderate	Biomarker	[22]
STXBP4	TTKS60G	moderate	Biomarker	[23]
AMOT	TTI48OS	Strong	Biomarker	[24]
APOH	TT2OUI9	Strong	Biomarker	[25]
ATP4A	TTF1QVM	Strong	Genetic Variation	[26]
ATP7B	TTOPO51	Strong	Biomarker	[27]
AURKA	TTPS3C0	Strong	Biomarker	[28]
CASP5	TTWR48J	Strong	Genetic Variation	[29]
CD274	TT8ZLTI	Strong	Altered Expression	[30]
CDKN1B	TTLGFVW	Strong	Altered Expression	[31]
CRHBP	TT3PKZE	Strong	Altered Expression	[32]
CRTC1	TT4GO0F	Strong	Biomarker	[33]
CYP11B1	TTIQUX7	Strong	Altered Expression	[34]
CYP11B2	TT9MNE2	Strong	Altered Expression	[34]
CYP1B1	TTI84H7	Strong	Genetic Variation	[35]
DIO1	TTU3X26	Strong	Altered Expression	[36]
DKK2	TTST5KX	Strong	Biomarker	[37]
EGLN2	TTMHFRY	Strong	Biomarker	[38]
EIF4EBP1	TTKGEBL	Strong	Biomarker	[39]
GRHL2	TTUGH4C	Strong	Biomarker	[40]
GRPR	TTC1MVT	Strong	Altered Expression	[41]
HAMP	TTRV5YJ	Strong	Biomarker	[42]
HPGDS	TTCYE56	Strong	Biomarker	[42]
HRC	TTR4FKD	Strong	Genetic Variation	[43]
IL32	TTD4G7L	Strong	Biomarker	[44]
KDM5C	TT94UCF	Strong	Posttranslational Modification	[45]
MC2R	TTPWFDX	Strong	Altered Expression	[46]
MELK	TTBZOTY	Strong	Biomarker	[47]
MET	TTNDSF4	Strong	Biomarker	[48]
MLANA	TT362RB	Strong	Biomarker	[49]
PAK4	TT7Y3BZ	Strong	Biomarker	[50]
PBRM1	TTH8ZRL	Strong	Biomarker	[51]
PDX1	TT8SGZK	Strong	Altered Expression	[52]
PGRMC1	TTY3LAZ	Strong	Biomarker	[53]
PINX1	TT4FJ3A	Strong	Biomarker	[54]
PLA2R1	TTHKW7D	Strong	Biomarker	[55]
PTEN	TTXJ3W7	Strong	Genetic Variation	[56]
RAF1	TTAN5W2	Strong	Biomarker	[39]
RALBP1	TTVSRUA	Strong	Genetic Variation	[57]
ROR1	TTDEJAU	Strong	Altered Expression	[58]
SDHD	TTVH9W8	Strong	Genetic Variation	[59]
SLC11A2	TT2IS7P	Strong	Altered Expression	[60]
SORD	TTLSRBZ	Strong	Biomarker	[61]
SYVN1	TT8XKYM	Strong	Biomarker	[62]
THRB	TTGER3L	Strong	Altered Expression	[63]
TMEM97	TT9NXW4	Strong	Altered Expression	[64]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[44]
TPH1	TTZSJHV	Strong	Biomarker	[42]
TPT1	TT3PTB6	Strong	Biomarker	[42]
TRPC4	TTX0H5W	Strong	Biomarker	[65]
TRPM8	TTXDKTO	Strong	Biomarker	[65]
UBE2T	TT0A1R8	Strong	Biomarker	[42]
AXL	TTZPY6J	Definitive	Biomarker	[66]
BRAF	TT0EOB8	Definitive	Biomarker	[39]
CCND1	TTFCJ7S	Definitive	Genetic Variation	[67]
EPAS1	TTWPA54	Definitive	Altered Expression	[68]
IL2	TTF89GD	Definitive	Biomarker	[69]
MAPK1	TT4TQBX	Definitive	Altered Expression	[20]
MAPK3	TT1MG9E	Definitive	Biomarker	[70]
NF2	TTZIK7P	Definitive	Genetic Variation	[71]
TNFSF10	TTA5MS9	Definitive	Altered Expression	[72]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ATP12A	DT5NLZA	Strong	Genetic Variation	[26]

This Disease Is Related to 8 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
GSTT1	DE3PKUG	Limited	Genetic Variation	[73]
ME1	DE97WM8	moderate	Biomarker	[74]
PER1	DE9HF0I	moderate	Altered Expression	[19]
PRODH	DEVJIHS	moderate	Biomarker	[75]
THOP1	DE95LJC	moderate	Biomarker	[76]
KYAT1	DES9MCU	Strong	Biomarker	[77]
UGT2B7	DEB3CV1	Strong	Altered Expression	[78]
CYP1A1	DE6OQ3W	Definitive	Genetic Variation	[79]

This Disease Is Related to 142 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CIAPIN1	OTWS90F9	Limited	Biomarker	[80]
COPS8	OTNAD2S4	Limited	Biomarker	[81]
CORO1C	OTXDF9T3	Limited	Biomarker	[82]
DLEC1	OTMKKBUW	Limited	Biomarker	[83]
MAPK13	OT0W9GE7	Limited	Altered Expression	[84]
NPRL2	OTOB10MO	Limited	Biomarker	[85]
PSMA5	OT38E6Y1	Limited	Altered Expression	[86]
RAP1GAP	OTC31ONQ	Limited	Altered Expression	[87]
SLC16A4	OT1YXBKC	Limited	Biomarker	[15]
SOSTDC1	OTAKDNSM	Limited	Biomarker	[88]
TCF21	OT393IMA	Limited	Altered Expression	[89]
TMEM106A	OTHTBYDN	Limited	Biomarker	[90]
ATG16L2	OTJYU0W8	Disputed	Biomarker	[91]
GABARAPL1	OT4U7SBG	Disputed	Altered Expression	[91]
ACYP2	OTRB4S6X	moderate	Genetic Variation	[92]
AP5M1	OTDLWEBL	moderate	Altered Expression	[17]
CBFA2T2	OTNOIB23	moderate	Altered Expression	[93]
CDK5RAP3	OTC0Q2QS	moderate	Biomarker	[94]
CHP1	OTHTXN1A	moderate	Biomarker	[95]
CHRDL1	OTGMWVVA	moderate	Biomarker	[96]
DBP	OTE0W7LN	moderate	Genetic Variation	[97]
ELOC	OT0XHHWP	moderate	Genetic Variation	[98]
ERCC6L	OTE9V7D9	moderate	Altered Expression	[99]
FAM83H	OTN0SF11	moderate	Biomarker	[100]
FNDC5	OT5CSK9X	moderate	Biomarker	[101]
FNIP2	OT7EX8JJ	moderate	Biomarker	[102]
FRK	OTEKV1SC	moderate	Biomarker	[103]
GABPB1	OTEXDEJN	moderate	Altered Expression	[104]
HAVCR1	OT184CRZ	moderate	Biomarker	[105]
KLHDC8B	OTKP6LCR	moderate	Biomarker	[96]
MAP1LC3C	OTM4ECDK	moderate	Altered Expression	[91]
MKS1	OT83W5PB	moderate	Biomarker	[74]
MTA2	OTCCYIQJ	moderate	Biomarker	[106]
NPAS2	OTMRT2TS	moderate	Biomarker	[19]
NR1D2	OT9CVF41	moderate	Biomarker	[19]
NSD2	OTQ6SW4R	moderate	Altered Expression	[107]
PANX2	OTAQ2S8R	moderate	Biomarker	[100]
PIK3R2	OTZSUQK5	moderate	Altered Expression	[93]
PLAC8	OT3SYRUJ	moderate	Biomarker	[108]
PLIN3	OT9ZA7MR	moderate	Biomarker	[109]
PPP1R12C	OT9Q86JO	moderate	Altered Expression	[93]
PPP1R13B	OTC88VQO	moderate	Altered Expression	[93]
RBX1	OTYA1UIO	moderate	Altered Expression	[110]
RGN	OTD04KB1	moderate	Altered Expression	[111]
RHOV	OTW4N3QN	moderate	Biomarker	[95]
RPL17	OTTYMPS6	moderate	Biomarker	[112]
SART1	OTHMOGO1	moderate	Altered Expression	[20]
SCUBE1	OT4JY1UY	moderate	Biomarker	[113]
SGK2	OTCTVSHF	moderate	Biomarker	[114]
SPATA2	OTOA45GL	moderate	Biomarker	[112]
SPOP	OTP0107S	moderate	Genetic Variation	[115]
SRSF2	OTVDHO6U	moderate	Biomarker	[116]
STARD13	OTB4U1HY	moderate	Biomarker	[117]
TBCK	OTP38GVK	moderate	Biomarker	[118]
TFEB	OTJUJJQY	moderate	Biomarker	[119]
TRAP1	OTNG0L8J	moderate	Altered Expression	[120]
AKT1S1	OT4JHN4Y	Strong	Altered Expression	[121]
ALDH9A1	OTNWHUJ1	Strong	Genetic Variation	[122]
AMER1	OT8EFJPM	Strong	Genetic Variation	[123]
APH1A	OT97F1TU	Strong	Genetic Variation	[124]
ATP1B1	OTTO6ZP4	Strong	Altered Expression	[125]
BBS2	OTPF9JIB	Strong	Biomarker	[126]
BCL2L12	OTS6IFZY	Strong	Biomarker	[127]
BCOR	OTG013AX	Strong	Biomarker	[128]
BRAP	OTB7BAFQ	Strong	Genetic Variation	[129]
BTG2	OTZF6K1H	Strong	Altered Expression	[130]
C1orf52	OT8RQW3W	Strong	Biomarker	[131]
C4orf46	OTXL7SLI	Strong	Biomarker	[132]
CABIN1	OT4G5CIK	Strong	Biomarker	[133]
CACYBP	OTJMZD2T	Strong	Biomarker	[134]
CAV2	OT1FGRQX	Strong	Biomarker	[135]
CCNG2	OTII38K2	Strong	Biomarker	[136]
CDCP1	OTD7RRWK	Strong	Biomarker	[137]
CDR2	OTD3ZJST	Strong	Biomarker	[38]
CHL1	OT6E6E8P	Strong	Biomarker	[138]
CHMP2B	OTZA7RJB	Strong	Altered Expression	[60]
COPS3	OTZWPJ24	Strong	Biomarker	[139]
CREB3L4	OTSGQGT2	Strong	Altered Expression	[140]
CUL1	OTXPE1UZ	Strong	Biomarker	[134]
DDT	OTF5HTYL	Strong	Biomarker	[141]
DERL3	OTRZRT6Q	Strong	Biomarker	[62]
DHRS2	OTFHWIY8	Strong	Biomarker	[142]
DMRT1	OT5PU9U1	Strong	Altered Expression	[60]
DNM3	OTDMUGCR	Strong	Biomarker	[42]
ELF5	OTLRU8YF	Strong	Altered Expression	[143]
EPB41L5	OTPPQPLU	Strong	Biomarker	[144]
ESCO2	OTJEMAQU	Strong	Biomarker	[42]
ESM1	OT331Y8V	Strong	Altered Expression	[145]
FEZ1	OTWCXPRE	Strong	Biomarker	[146]
FIGNL1	OTKII63K	Strong	Biomarker	[42]
FLCN	OTVM78XM	Strong	Genetic Variation	[147]
FNIP1	OTB1CC41	Strong	Biomarker	[148]
FRZB	OTTO3DPY	Strong	Biomarker	[149]
GATA5	OTO81B63	Strong	Biomarker	[150]
GDF9	OTNTVKVU	Strong	Altered Expression	[151]
GIPC1	OTXLVCPJ	Strong	Biomarker	[152]
GLRX3	OTUPAU1N	Strong	Biomarker	[153]
HLTF	OTRX2OSF	Strong	Biomarker	[154]
JADE1	OTBPJIRI	Strong	Altered Expression	[155]
KANK1	OT2E7A6W	Strong	Altered Expression	[156]
KLF8	OTUC5CDB	Strong	Altered Expression	[157]
KLLN	OTV3FPH0	Strong	Posttranslational Modification	[158]
LARP6	OTUQ9QS9	Strong	Biomarker	[159]
LRRC4	OT7XJ70N	Strong	Biomarker	[131]
LZTS1	OTXXL864	Strong	Biomarker	[146]
MAML1	OTQA4DDN	Strong	Biomarker	[160]
MCPH1	OTYT3TT5	Strong	Altered Expression	[161]
MITF	OT6XJCZH	Strong	Genetic Variation	[162]
MYBBP1A	OTIVEMIU	Strong	Biomarker	[163]
MYCL	OT1MFQ5U	Strong	Genetic Variation	[164]
NDRG1	OTVO66BO	Strong	Biomarker	[165]
NMU	OTW9X7BQ	Strong	Biomarker	[166]
OSGIN1	OT9KIVZW	Strong	Biomarker	[167]
PDHX	OTG7O271	Strong	Altered Expression	[52]
PHLDA1	OTFTWMIQ	Strong	Biomarker	[168]
PLIN2	OTRXJ9UN	Strong	Biomarker	[169]
PYCR1	OTQHB52T	Strong	Biomarker	[170]
QKI	OTTAUGLB	Strong	Biomarker	[171]
RAB27B	OTPF9D0K	Strong	Altered Expression	[172]
RADIL	OTQTRGMB	Strong	Biomarker	[173]
RANBP1	OTQE226K	Strong	Biomarker	[42]
RASSF5	OT6Q41I2	Strong	Biomarker	[174]
RCHY1	OTAE7504	Strong	Altered Expression	[175]
RHEB	OTFLTSEC	Strong	Genetic Variation	[176]
RPS15A	OT0BUA12	Strong	Genetic Variation	[177]
SARDH	OTQ49Q27	Strong	Biomarker	[61]
SDHB	OTRE1M1T	Strong	Biomarker	[61]
SDS	OT5WTJ2M	Strong	Biomarker	[61]
SF3B3	OTAC9LZT	Strong	Altered Expression	[178]
SFPQ	OTLCIAPJ	Strong	Genetic Variation	[124]
ST6GALNAC6	OT3C3VWX	Strong	Altered Expression	[179]
SUPT20H	OTTMC0LH	Strong	Altered Expression	[180]
TCHP	OTVDMHSY	Strong	Altered Expression	[181]
TESC	OTI8C76M	Strong	Biomarker	[182]
TFE3	OTM99ZWH	Strong	Genetic Variation	[183]
TMEM45A	OT54KJG6	Strong	Altered Expression	[184]
TOP3B	OTNFEUOO	Strong	Genetic Variation	[185]
TRIP11	OT4FJEAR	Strong	Biomarker	[186]
RNF139	OT0PR1X5	Definitive	Genetic Variation	[187]
SEMA3B	OTCZCPMS	Definitive	Genetic Variation	[188]
TMEM132D	OTV6I4Z0	Definitive	Biomarker	[189]
TSC2	OT47LWI9	Definitive	Biomarker	[190]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5889).
• [2] ClinicalTrials.gov (NCT00004890)Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer in National Cancer Institute (NCI).
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005345)
• [4] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012140)
• [5] MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies.Mol Biol Rep. 2012 Jul;39(7):7237-49. doi: 10.1007/s11033-012-1554-7. Epub 2012 Feb 4.
• [6] Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.J Transl Med. 2009 Dec 9;7:103. doi: 10.1186/1479-5876-7-103.
• [7] Downregulation of ATP1A1 promotes cancer development in renal cell carcinoma.Clin Proteomics. 2017 May 4;14:15. doi: 10.1186/s12014-017-9150-4. eCollection 2017.
• [8] Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.Cancer Discov. 2017 Sep;7(9):1030-1045. doi: 10.1158/2159-8290.CD-16-1414. Epub 2017 May 19.
• [9] Growth suppression induced by the TRC8 hereditary kidney cancer gene is dependent upon JAB1/CSN5.Oncogene. 2005 May 12;24(21):3503-11. doi: 10.1038/sj.onc.1208509.
• [10] Exogenous DKK-3/REIC inhibits Wnt/-catenin signaling and cell proliferation in human kidney cancer KPK1.Oncol Lett. 2017 Nov;14(5):5638-5642. doi: 10.3892/ol.2017.6833. Epub 2017 Aug 28.
• [11] IL-16 rs4778889 polymorphism contribution to the development of renal cell cancer in a Chinese population.Genet Mol Res. 2016 Jun 10;15(2). doi: 10.4238/gmr.15027553.
• [12] Ascorbate antagonizes nickel ion to regulate JMJD1A expression in kidney cancer cells.Acta Biochim Biophys Sin (Shanghai). 2012 Apr;44(4):330-8. doi: 10.1093/abbs/gms004. Epub 2012 Feb 7.
• [13] Calcitriol induces cell senescence of kidney cancer through JMJD3 mediated histone demethylation.Oncotarget. 2017 Oct 26;8(59):100187-100195. doi: 10.18632/oncotarget.22124. eCollection 2017 Nov 21.
• [14] Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues.PLoS One. 2013 Nov 13;8(11):e78885. doi: 10.1371/journal.pone.0078885. eCollection 2013.
• [15] Monocarboxylate transporter 1 and monocarboxylate transporter 4 in cancer-endothelial co-culturing microenvironments promote proliferation, migration, and invasion of renal cancer cells.Cancer Cell Int. 2019 Jun 28;19:170. doi: 10.1186/s12935-019-0889-8. eCollection 2019.
• [16] The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells.Cancer Gene Ther. 2003 Jan;10(1):14-22. doi: 10.1038/sj.cgt.7700525.
• [17] Landscape of cancer diagnostic biomarkers from specifically expressed genes.Brief Bioinform. 2020 Dec 1;21(6):2175-2184. doi: 10.1093/bib/bbz131.
• [18] Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.J Control Release. 2017 Jan 28;246:39-45. doi: 10.1016/j.jconrel.2016.11.023. Epub 2016 Nov 24.
• [19] Research on circadian clock genes in common abdominal malignant tumors.Chronobiol Int. 2019 Jul;36(7):906-918. doi: 10.1080/07420528.2018.1477792. Epub 2019 Apr 24.
• [20] Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.Mol Cancer Res. 2019 May;17(5):1220-1232. doi: 10.1158/1541-7786.MCR-18-1080. Epub 2019 Jan 31.
• [21] High kinesin family member 11 expression predicts poor prognosis in patients with clear cell renal cell carcinoma.J Clin Pathol. 2019 May;72(5):354-362. doi: 10.1136/jclinpath-2018-205390. Epub 2019 Feb 28.
• [22] HOXA11-AS promotes the growth and invasion of renal cancer by sponging miR-146b-5p to upregulate MMP16 expression.J Cell Physiol. 2018 Dec;233(12):9611-9619. doi: 10.1002/jcp.26864. Epub 2018 Jun 28.
• [23] Elucidation of WW domain ligand binding specificities in the Hippo pathway reveals STXBP4 as YAP inhibitor.EMBO J. 2020 Jan 2;39(1):e102406. doi: 10.15252/embj.2019102406. Epub 2019 Nov 29.
• [24] Angiomotin Family Members: Oncogenes or Tumor Suppressors?.Int J Biol Sci. 2017 Jun 1;13(6):772-781. doi: 10.7150/ijbs.19603. eCollection 2017.
• [25] Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel-Lindau patients.Biomarkers. 2018 Mar;23(2):123-130. doi: 10.1080/1354750X.2016.1269132. Epub 2016 Dec 22.
• [26] Medication use and kidney cancer risk: Apopulation-based study.Eur J Cancer. 2017 Sep;83:203-210. doi: 10.1016/j.ejca.2017.07.001. Epub 2017 Jul 24.
• [27] Role of Atp7b gene in spontaneous and N-diethylnitrosamine-induced carcinogenesis in a new congenic strain, WKAH.C-Atp7b rats.Jpn J Cancer Res. 2001 Aug;92(8):841-7. doi: 10.1111/j.1349-7006.2001.tb01170.x.
• [28] Expression of selected Aurora A kinase substrates in solely estrogen-induced ectopic uterine stem cell tumors in the Syrian hamster kidney.Adv Exp Med Biol. 2008;617:411-8. doi: 10.1007/978-0-387-69080-3_39.
• [29] An analysis of growth, differentiation and apoptosis genes with risk of renal cancer.PLoS One. 2009 Mar 24;4(3):e4895. doi: 10.1371/journal.pone.0004895.
• [30] Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer.Mol Cancer Res. 2020 Feb;18(2):324-339. doi: 10.1158/1541-7786.MCR-19-0517. Epub 2019 Oct 31.
• [31] TMIGD1 acts as a tumor suppressor through regulation of p21Cip1/p27Kip1 in renal cancer.Oncotarget. 2017 Dec 26;9(11):9672-9684. doi: 10.18632/oncotarget.23822. eCollection 2018 Feb 9.
• [32] Reduced mRNA expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer.BMC Cancer. 2013 Apr 22;13:199. doi: 10.1186/1471-2407-13-199.
• [33] microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion.PLoS One. 2012;7(6):e37366. doi: 10.1371/journal.pone.0037366. Epub 2012 Jun 4.
• [34] Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas. Eur J Endocrinol. 2002 Dec;147(6):795-802.
• [35] Association of CYP1B1 L432V polymorphism with urinary cancer susceptibility: a meta-analysis.Diagn Pathol. 2014 Jun 9;9:113. doi: 10.1186/1746-1596-9-113.
• [36] Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system.PLoS One. 2017 Dec 22;12(12):e0190179. doi: 10.1371/journal.pone.0190179. eCollection 2017.
• [37] Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways.Clin Cancer Res. 2009 Sep 15;15(18):5678-87. doi: 10.1158/1078-0432.CCR-09-0558.
• [38] Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.Oncogene. 2009 Sep 17;28(37):3274-85. doi: 10.1038/onc.2009.186. Epub 2009 Jul 6.
• [39] ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.Toxicol Sci. 2011 Nov;124(1):75-87. doi: 10.1093/toxsci/kfr203. Epub 2011 Aug 2.
• [40] Integrative bioinformatics analysis reveals new prognostic biomarkers of clear cell renal cell carcinoma.Clin Chem. 2014 Oct;60(10):1314-26. doi: 10.1373/clinchem.2014.225854. Epub 2014 Aug 19.
• [41] Expression and function of gastrin-releasing peptide (GRP) in normal and cancerous urological tissues.BJU Int. 2014 Mar;113 Suppl 2:40-7. doi: 10.1111/bju.12594.
• [42] Investigation of the early-response genes in chemical-induced renal carcinogenicity for the prediction of chemical carcinogenicity in rats.J Toxicol Sci. 2017;42(2):175-181. doi: 10.2131/jts.42.175.
• [43] Linking human genetics with molecular medicine: will hereditary renal cancer play a major role?.Cancer Biol Ther. 2004 May;3(5):441-6. doi: 10.4161/cbt.3.5.807. Epub 2004 May 18.
• [44] Expression of acidosis-dependent genes in human cancer nests.Mol Clin Oncol. 2014 Nov;2(6):1160-1166. doi: 10.3892/mco.2014.344. Epub 2014 Jul 11.
• [45] Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.J Clin Invest. 2015 Dec;125(12):4625-37. doi: 10.1172/JCI81040. Epub 2015 Nov 9.
• [46] Expression of adrenocorticotropin receptor gene in adrenocortical adenomas from patients with Cushing syndrome: possible contribution for the autonomous production of cortisol.Ann Surg. 2001 Jul;234(1):85-91. doi: 10.1097/00000658-200107000-00013.
• [47] Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.Oncotarget. 2016 Apr 5;7(14):17652-64. doi: 10.18632/oncotarget.7755.
• [48] C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.Cells. 2019 Mar 22;8(3):272. doi: 10.3390/cells8030272.
• [49] Melanotic MiT family translocation neoplasms: Expanding the clinical and molecular spectrum of this unique entity of tumors.Pathol Res Pract. 2017 Nov;213(11):1412-1418. doi: 10.1016/j.prp.2017.08.004. Epub 2017 Aug 25.
• [50] Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.Mol Cancer Ther. 2016 Sep;15(9):2119-29. doi: 10.1158/1535-7163.MCT-16-0197. Epub 2016 Jul 7.
• [51] High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of PBRM1.Mol Oncol. 2019 Apr;13(4):811-828. doi: 10.1002/1878-0261.12434. Epub 2019 Feb 2.
• [52] Tissue MicroArray analyses of pancreatic duodenal homeobox-1 in human cancers.World J Surg. 2005 Mar;29(3):334-8. doi: 10.1007/s00268-004-7823-4.
• [53] PGRMC1 Is a Novel Potential Tumor Biomarker of Human Renal Cell Carcinoma Based on Quantitative Proteomic and Integrative Biological Assessments. PLoS One. 2017 Jan 20;12(1):e0170453.
• [54] PinX1 represses renal cancer angiogenesis via the mir-125a-3p/VEGF signaling pathway.Angiogenesis. 2019 Nov;22(4):507-519. doi: 10.1007/s10456-019-09675-z. Epub 2019 Jun 28.
• [55] Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth.Oncotarget. 2014 Feb 28;5(4):1004-13. doi: 10.18632/oncotarget.1681.
• [56] PTEN Mutation Identified in Patient Diagnosed with Simultaneous Multiple Cancers.Cancer Res Treat. 2019 Jan;51(1):402-407. doi: 10.4143/crt.2017.579. Epub 2018 Feb 27.
• [57] Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis.Mol Cancer Ther. 2011 Jan;10(1):16-28. doi: 10.1158/1535-7163.MCT-10-0699.
• [58] Comparative genomics on ROR1 and ROR2 orthologs.Oncol Rep. 2005 Nov;14(5):1381-4. doi: 10.3892/or.14.5.1381.
• [59] Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.J Urol. 2012 Dec;188(6):2063-71. doi: 10.1016/j.juro.2012.08.030. Epub 2012 Oct 18.
• [60] Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer.Clin Cancer Res. 2013 Jul 1;19(13):3345-52. doi: 10.1158/1078-0432.CCR-13-0304. Epub 2013 Apr 30.
• [61] Urological cancer related to familial syndromes.Int Braz J Urol. 2017 Mar-Apr;43(2):192-201. doi: 10.1590/S1677-5538.IBJU.2016.0125.
• [62] Loss of der(3) in renal carcinoma cells of a patient with constitutional t(3;12).Hum Genet. 1988 Feb;78(2):148-50. doi: 10.1007/BF00278186.
• [63] Epigenetic regulation of thyroid hormone receptor beta in renal cancer.PLoS One. 2014 May 21;9(5):e97624. doi: 10.1371/journal.pone.0097624. eCollection 2014.
• [64] Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract.Histol Histopathol. 2004 Oct;19(4):1021-31. doi: 10.14670/HH-19.1021.
• [65] Data-driven Analysis of TRP Channels in Cancer: Linking Variation in Gene Expression to Clinical Significance.Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):83-90.
• [66] Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase.Clin Cancer Res. 2017 Jun 15;23(12):2928-2933. doi: 10.1158/1078-0432.CCR-17-0189. Epub 2017 Mar 13.
• [67] Genetic polymorphisms in cyclin D1 are associated with risk of renal cell cancer in the Chinese population.Oncotarget. 2017 Sep 8;8(46):80889-80899. doi: 10.18632/oncotarget.20720. eCollection 2017 Oct 6.
• [68] Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high HIF2A mRNA levels in clear cell renal cell carcinoma.J Biol Chem. 2019 Mar 8;294(10):3760-3771. doi: 10.1074/jbc.RA118.004902. Epub 2019 Jan 7.
• [69] Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma.Neurosurg Rev. 2019 Jun;42(2):351-369. doi: 10.1007/s10143-018-0953-1. Epub 2018 Feb 17.
• [70] Synergistic combination of YS-1 and adriamycin inhibits human renal cancer through ERK1/2 signaling pathway invitro and invivo.Oncol Rep. 2017 Mar;37(3):1756-1764. doi: 10.3892/or.2017.5373. Epub 2017 Jan 16.
• [71] YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells.Dev Cell. 2019 May 6;49(3):425-443.e9. doi: 10.1016/j.devcel.2019.04.014.
• [72] Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells.Carcinogenesis. 2008 Sep;29(9):1734-41. doi: 10.1093/carcin/bgn132. Epub 2008 Jun 9.
• [73] Occupational exposures and genetic susceptibility to urinary tract cancers: a systematic review and meta-analysis.Eur J Cancer Prev. 2018 Sep;27(5):468-476. doi: 10.1097/CEJ.0000000000000364.
• [74] Improved Total Synthesis of Tubulysins and Design, Synthesis, and Biological Evaluation of New Tubulysins with Highly Potent Cytotoxicities against Cancer Cells as Potential Payloads for Antibody-Drug Conjugates.J Am Chem Soc. 2018 Mar 14;140(10):3690-3711. doi: 10.1021/jacs.7b12692. Epub 2018 Jan 30.
• [75] miR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer. Oncogene. 2010 Sep 2;29(35):4914-24.
• [76] Efficient proximal gradient algorithm for inference of differential gene networks.BMC Bioinformatics. 2019 May 2;20(1):224. doi: 10.1186/s12859-019-2749-x.
• [77] Occupational trichloroethylene exposure and renal carcinoma risk: evidence of genetic susceptibility by reductive metabolism gene variants.Cancer Res. 2010 Aug 15;70(16):6527-36. doi: 10.1158/0008-5472.CAN-09-4167. Epub 2010 Jul 27.
• [78] Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer.Pharmacogenet Genomics. 2013 Dec;23(12):684-96. doi: 10.1097/FPC.0000000000000008.
• [79] Relationship between CYP1A1 genetic polymorphisms and renal cancer in China.Asian Pac J Cancer Prev. 2011;12(9):2163-6.
• [80] Expression of CIAPIN1 in human colorectal cancer and its correlation with prognosis.BMC Cancer. 2010 Sep 3;10:477. doi: 10.1186/1471-2407-10-477.
• [81] Mutation screening of ACKR3 and COPS8 in kidney cancer cases from the CONFIRM study.Fam Cancer. 2017 Jul;16(3):411-416. doi: 10.1007/s10689-016-9961-x.
• [82] miR-26 suppresses renal cell cancer via down-regulating coronin-3.Mol Cell Biochem. 2020 Jan;463(1-2):137-146. doi: 10.1007/s11010-019-03636-2. Epub 2019 Oct 8.
• [83] Evidence of a tumour suppressor function for DLEC1 in human breast cancer.Anticancer Res. 2010 Apr;30(4):1079-82.
• [84] MAPK13 is preferentially expressed in gynecological cancer stem cells and has a role in the tumor-initiation.Biochem Biophys Res Commun. 2016 Apr 15;472(4):643-7. doi: 10.1016/j.bbrc.2016.03.004. Epub 2016 Mar 9.
• [85] Biological characteristics of renal cancer cells after CTP-mediated cancer suppressor gene NPRL2 protein treatment.Biol Chem. 2016 Nov 1;397(11):1163-1171. doi: 10.1515/hsz-2016-0143.
• [86] The transcription levels and prognostic values of seven proteasome alpha subunits in human cancers.Oncotarget. 2017 Jan 17;8(3):4501-4519. doi: 10.18632/oncotarget.13885.
• [87] Rap1GAP regulates renal cell carcinoma invasion.Cancer Lett. 2012 Jul 1;320(1):65-71. doi: 10.1016/j.canlet.2012.01.022. Epub 2012 Jan 20.
• [88] Defining Signatures of Arm-Wise Copy Number Change and Their Associated Drivers in Kidney Cancers.Int J Mol Sci. 2019 Nov 16;20(22):5762. doi: 10.3390/ijms20225762.
• [89] TCF21 hypermethylation regulates renal tumor cell clonogenic proliferation and migration.Mol Oncol. 2018 Feb;12(2):166-179. doi: 10.1002/1878-0261.12149. Epub 2017 Dec 14.
• [90] TMEM106A inhibits cell proliferation, migration, and induces apoptosis of lung cancer cells.J Cell Biochem. 2019 May;120(5):7825-7833. doi: 10.1002/jcb.28057. Epub 2018 Nov 19.
• [91] Cross-cancer profiling of molecular alterations within the human autophagy interaction network.Autophagy. 2015;11(9):1668-87. doi: 10.1080/15548627.2015.1067362.
• [92] Association between ACYP2 polymorphisms and the risk of renal cell cancer.Mol Genet Genomic Med. 2019 Nov;7(11):e966. doi: 10.1002/mgg3.966. Epub 2019 Sep 5.
• [93] Anticancer activity of Schiff base-Poloxamer P85 combination against kidney cancer.Int Urol Nephrol. 2018 Feb;50(2):247-255. doi: 10.1007/s11255-017-1782-9. Epub 2017 Dec 29.
• [94] CDK5RAP3 Participates in Autophagy Regulation and Is Downregulated in Renal Cancer.Dis Markers. 2019 Apr 2;2019:6171782. doi: 10.1155/2019/6171782. eCollection 2019.
• [95] Quantitative Contour Analysis as an Image-based Discriminator Between Benign and Malignant Renal Tumors.Urology. 2018 Apr;114:121-127. doi: 10.1016/j.urology.2017.12.018. Epub 2018 Jan 2.
• [96] De novo design of thioredoxin reductase-targeted heterometallic titanocene-gold compounds of chlorambucil for mechanistic insights into renal cancer.Chem Commun (Camb). 2019 Dec 19;56(2):297-300. doi: 10.1039/c9cc07406f.
• [97] Blood pressure and kidney cancer risk: meta-analysis of prospective studies.J Hypertens. 2017 Jul;35(7):1333-1344. doi: 10.1097/HJH.0000000000001286.
• [98] Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?.Histopathology. 2019 Jan;74(1):60-67. doi: 10.1111/his.13749.
• [99] ERCC6L, a DNA helicase, is involved in cell proliferation and associated with survival and progress in breast and kidney cancers.Oncotarget. 2017 Jun 27;8(26):42116-42124. doi: 10.18632/oncotarget.14998.
• [100] The Expression Patterns of FAM83H and PANX2 Are Associated With Shorter Survival of Clear Cell Renal Cell Carcinoma Patients.Front Oncol. 2019 Jan 22;9:14. doi: 10.3389/fonc.2019.00014. eCollection 2019.
• [101] The Diagnostic Value of FNDC5/Irisin in Renal Cell Cancer.Int Braz J Urol. 2018 Jul-Aug;44(4):734-739. doi: 10.1590/S1677-5538.IBJU.2017.0404.
• [102] Nutrient-induced FNIP degradation by SCF-TRCP regulates FLCN complex localization and promotes renal cancer progression.Oncotarget. 2017 Feb 7;8(6):9947-9960. doi: 10.18632/oncotarget.14221.
• [103] miR-19 promotes the proliferation of clear cell renal cell carcinoma by targeting the FRK-PTEN axis.Onco Targets Ther. 2019 Apr 10;12:2713-2727. doi: 10.2147/OTT.S199238. eCollection 2019.
• [104] Knockdown of GA-binding protein subunit 1 inhibits cell proliferation via p21 induction in renal cell carcinoma.Int J Oncol. 2018 Aug;53(2):886-894. doi: 10.3892/ijo.2018.4411. Epub 2018 May 17.
• [105] KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study.Clin Cancer Res. 2018 Nov 15;24(22):5594-5601. doi: 10.1158/1078-0432.CCR-18-1496. Epub 2018 Jul 23.
• [106] MTA2 as a Potential Biomarker and Its Involvement in Metastatic Progression of Human Renal Cancer by miR-133b Targeting MMP-9.Cancers (Basel). 2019 Nov 23;11(12):1851. doi: 10.3390/cancers11121851.
• [107] Knockdown of NSD2 Suppresses Renal Cell Carcinoma Metastasis by Inhibiting Epithelial-Mesenchymal Transition.Int J Med Sci. 2019 Sep 20;16(10):1404-1411. doi: 10.7150/ijms.36128. eCollection 2019.
• [108] Knockout of the Placenta Specific 8 Gene Affects the Proliferation and Migration of Human Embryonic Kidney 293T Cell.Cell Biochem Biophys. 2020 Mar;78(1):55-64. doi: 10.1007/s12013-019-00893-2. Epub 2019 Nov 6.
• [109] PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma.Urol Oncol. 2018 Jul;36(7):343.e9-343.e19. doi: 10.1016/j.urolonc.2018.04.006.
• [110] Expression of Ring Box-1 protein and its relationship with Fuhrman grade and other clinical-pathological parameters in renal cell cancer.Urol Oncol. 2020 Jan;38(1):6.e17-6.e22. doi: 10.1016/j.urolonc.2019.09.019. Epub 2019 Oct 23.
• [111] Prolonged survival of renal cancer patients is concomitant with a higher regucalcin gene expression in tumor tissues: Overexpression of regucalcin suppresses the growth of human renal cell carcinoma cells in vitro.Int J Oncol. 2019 Jan;54(1):188-198. doi: 10.3892/ijo.2018.4611. Epub 2018 Oct 30.
• [112] A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy.Mol Cancer Ther. 2019 Jun;18(6):1081-1091. doi: 10.1158/1535-7163.MCT-18-0737. Epub 2019 Apr 23.
• [113] SCUBE1: a promising biomarker in renal cell cancer.Int Braz J Urol. 2017 Jul-Aug;43(4):638-643. doi: 10.1590/S1677-5538.IBJU.2016.0316.
• [114] SGK2 promotes renal cancer progression via enhancing ERK 1/2 and AKT phosphorylation.Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):2756-2767. doi: 10.26355/eurrev_201904_17549.
• [115] The ubiquitin ligase adaptor SPOP in cancer.FEBS J. 2019 Oct;286(20):3946-3958. doi: 10.1111/febs.15056. Epub 2019 Sep 18.
• [116] microRNA-mediated regulation of splicing factors SRSF1, SRSF2 and hnRNP A1 in context of their alternatively spliced 3'UTRs.Exp Cell Res. 2018 Feb 15;363(2):208-217. doi: 10.1016/j.yexcr.2018.01.009. Epub 2018 Jan 10.
• [117] Rho GTPase Activating Protein 24 (ARHGAP24) Silencing Promotes Lung Cancer Cell Migration and Invasion by Activating -Catenin Signaling.Med Sci Monit. 2019 Jan 1;25:21-31. doi: 10.12659/MSM.911503.
• [118] MiR-1208 Increases the Sensitivity to Cisplatin by Targeting TBCK in Renal Cancer Cells.Int J Mol Sci. 2019 Jul 19;20(14):3540. doi: 10.3390/ijms20143540.
• [119] Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.Virchows Arch. 2019 May;474(5):625-631. doi: 10.1007/s00428-019-02526-8. Epub 2019 Jan 31.
• [120] TRAP1 Regulation of Cancer Metabolism: Dual Role as Oncogene or Tumor Suppressor.Genes (Basel). 2018 Apr 5;9(4):195. doi: 10.3390/genes9040195.
• [121] Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.PLoS One. 2011;6(8):e23919. doi: 10.1371/journal.pone.0023919. Epub 2011 Aug 23.
• [122] Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancer.PLoS One. 2015 Mar 31;10(3):e0122589. doi: 10.1371/journal.pone.0122589. eCollection 2015.
• [123] Genetic and Molecular Insights Into Genotype-Phenotype Relationships in Osteopathia Striata With Cranial Sclerosis (OSCS) Through the Analysis of Novel Mouse Wtx Mutant Alleles.J Bone Miner Res. 2018 May;33(5):875-887. doi: 10.1002/jbmr.3387. Epub 2018 Mar 1.
• [124] Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts.Am J Surg Pathol. 2009 Dec;33(12):1894-901. doi: 10.1097/PAS.0b013e3181ba7a5f.
• [125] Epigenetic silencing of Na,K-ATPase 1 subunit gene ATP1B1 by methylation in clear cell renal cell carcinoma.Epigenetics. 2014 Apr;9(4):579-86. doi: 10.4161/epi.27795. Epub 2014 Jan 22.
• [126] Renal cancer and malformations in relatives of patients with Bardet-Biedl syndrome.Nephrol Dial Transplant. 2000 Dec;15(12):1977-85. doi: 10.1093/ndt/15.12.1977.
• [127] Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.Tumour Biol. 2015 May;36(5):3197-207. doi: 10.1007/s13277-014-2190-8. Epub 2015 Apr 2.
• [128] Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney.Nat Genet. 2015 Aug;47(8):861-3. doi: 10.1038/ng.3338. Epub 2015 Jun 22.
• [129] A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1.J Cancer. 2017 Aug 21;8(13):2643-2652. doi: 10.7150/jca.20234. eCollection 2017.
• [130] Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma.Cancer Res. 2004 Mar 1;64(5):1632-8. doi: 10.1158/0008-5472.can-03-1687.
• [131] Inhibition of the JNK signalling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression.Br J Pharmacol. 2009 Nov;158(5):1405-12. doi: 10.1111/j.1476-5381.2009.00455.x. Epub 2009 Aug 13.
• [132] Expression and clinical significance of RCDG1 in renal cell carcinoma: a novel renal cancerassociated gene.Mol Med Rep. 2014 Sep;10(3):1583-9. doi: 10.3892/mmr.2014.2388. Epub 2014 Jul 16.
• [133] Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.Sci Rep. 2017 Jul 19;7(1):5900. doi: 10.1038/s41598-017-05455-1.
• [134] Expression and clinical significance of CacyBP/SIP in pancreatic cancer.Pancreatology. 2008;8(4-5):470-7. doi: 10.1159/000151774. Epub 2008 Sep 3.
• [135] CAV2 promotes the growth of renal cell carcinoma through the EGFR/PI3K/Akt pathway.Onco Targets Ther. 2018 Sep 25;11:6209-6216. doi: 10.2147/OTT.S172803. eCollection 2018.
• [136] Change in expression of cyclin G2 in kidney cancer cell and its significance.Tumour Biol. 2014 Apr;35(4):3177-83. doi: 10.1007/s13277-013-1415-6. Epub 2013 Nov 23.
• [137] VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration.Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1931-6. doi: 10.1073/pnas.1011777108. Epub 2011 Jan 13.
• [138] Differential expression of CHL1 gene during development of major human cancers.PLoS One. 2011 Mar 7;6(3):e15612. doi: 10.1371/journal.pone.0015612.
• [139] Overexpression of COPS3 promotes clear cell renal cell carcinoma progression via regulation of Phospho-AKT(Thr308), Cyclin D1 and Caspase-3.Exp Cell Res. 2018 Apr 15;365(2):163-170. doi: 10.1016/j.yexcr.2018.02.025. Epub 2018 Feb 23.
• [140] Oncogenic cAMP responsive element binding protein 1 is overexpressed upon loss of tumor suppressive miR-10b-5p and miR-363-3p in renal cancer.Oncol Rep. 2016 Apr;35(4):1967-78. doi: 10.3892/or.2016.4579. Epub 2016 Jan 20.
• [141] Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis.J Biol Chem. 2014 Feb 7;289(6):3713-23. doi: 10.1074/jbc.M113.500694. Epub 2013 Dec 19.
• [142] Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell.Cancer Biol Ther. 2016 Jun 2;17(6):664-73. doi: 10.1080/15384047.2016.1190485. Epub 2016 May 19.
• [143] The Ets transcription factor ELF5 functions as a tumor suppressor in the kidney.Twin Res Hum Genet. 2011 Aug;14(4):316-22. doi: 10.1375/twin.14.4.316.
• [144] High expression of EPB41L5, an integral component of the Arf6-driven mesenchymal program, correlates with poor prognosis of squamous cell carcinoma of the tongue.Cell Commun Signal. 2016 Nov 21;14(1):28. doi: 10.1186/s12964-016-0151-0.
• [145] Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer.Exp Cell Res. 2007 Apr 15;313(7):1285-94. doi: 10.1016/j.yexcr.2007.01.021. Epub 2007 Feb 6.
• [146] Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases.BMC Urol. 2004 Sep 9;4:11. doi: 10.1186/1471-2490-4-11.
• [147] Renal transplantation in Birt-Hogg-Dub syndrome: should we?.BMC Nephrol. 2018 Oct 16;19(1):267. doi: 10.1186/s12882-018-1064-5.
• [148] Birt-Hogg-Dub syndrome: from gene discovery to molecularly targeted therapies.Fam Cancer. 2013 Sep;12(3):357-64. doi: 10.1007/s10689-012-9574-y.
• [149] Role of secreted frizzled-related protein 3 in human renal cell carcinoma.Cancer Res. 2010 Mar 1;70(5):1896-905. doi: 10.1158/0008-5472.CAN-09-3549. Epub 2010 Feb 16.
• [150] GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.BJU Int. 2012 Jul;110(2 Pt 2):E144-52. doi: 10.1111/j.1464-410X.2011.10862.x. Epub 2012 Jan 30.
• [151] Loss of expression of growth differentiation factor-9 (GDF9) in human kidney cancer and regulation of growth and migration of kidney cancer cells by GDF9.Anticancer Res. 2012 Oct;32(10):4375-83.
• [152] RGS-GAIP-interacting protein controls breast cancer progression.Mol Cancer Res. 2010 Dec;8(12):1591-600. doi: 10.1158/1541-7786.MCR-10-0209. Epub 2010 Oct 27.
• [153] Preferential overexpression of glutaredoxin3 in human colon and lung carcinoma.Cancer Epidemiol. 2009 Oct;33(3-4):281-7. doi: 10.1016/j.canep.2009.08.006. Epub 2009 Sep 30.
• [154] Early expression of the Helicase-Like Transcription Factor (HLTF/SMARCA3) in an experimental model of estrogen-induced renal carcinogenesis.Mol Cancer. 2006 Jun 8;5:23. doi: 10.1186/1476-4598-5-23.
• [155] Structural basis for renal cancer by the dynamics of pVHL-dependent JADE1 stabilization and -catenin regulation.Prog Biophys Mol Biol. 2019 Aug;145:65-77. doi: 10.1016/j.pbiomolbio.2018.12.005. Epub 2018 Dec 7.
• [156] Upregulation of the Kank1 gene-induced brain glioma apoptosis and blockade of the cell cycle in G0/G1 phase.Int J Oncol. 2014 Mar;44(3):797-804. doi: 10.3892/ijo.2014.2247. Epub 2014 Jan 8.
• [157] Expression of Kruppel-like factor 8 and Ki67 in lung adenocarcinoma and prognosis.Exp Ther Med. 2017 Aug;14(2):1351-1356. doi: 10.3892/etm.2017.4632. Epub 2017 Jun 20.
• [158] Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA. 2010 Dec 22;304(24):2724-31. doi: 10.1001/jama.2010.1877.
• [159] Human renal adipose tissue from normal and tumor kidney: its influence on renal cell carcinoma.Oncotarget. 2019 Sep 10;10(52):5454-5467. doi: 10.18632/oncotarget.27157. eCollection 2019 Sep 10.
• [160] MAML1 acts cooperatively with EGR1 to activate EGR1-regulated promoters: implications for nephrogenesis and the development of renal cancer.PLoS One. 2012;7(9):e46001. doi: 10.1371/journal.pone.0046001. Epub 2012 Sep 27.
• [161] Primary microcephaly gene MCPH1 shows a novel molecular biomarker of human renal carcinoma and is regulated by miR-27a.Int J Clin Exp Pathol. 2014 Jul 15;7(8):4895-903. eCollection 2014.
• [162] Exploring the hereditary background of renal cancer in Denmark.PLoS One. 2019 Apr 29;14(4):e0215725. doi: 10.1371/journal.pone.0215725. eCollection 2019.
• [163] Loss of MYBBP1A Induces Cancer Stem Cell Activity in Renal Cancer.Cancers (Basel). 2019 Feb 18;11(2):235. doi: 10.3390/cancers11020235.
• [164] L-MYC allelotype in renal cell carcinoma.Cancer Genet Cytogenet. 1996 May;88(1):66-8. doi: 10.1016/0165-4608(95)00275-8.
• [165] Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers.BMC Genet. 2004 Sep 2;5:27. doi: 10.1186/1471-2156-5-27.
• [166] Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells.Mol Cancer. 2011 Jul 26;10:89. doi: 10.1186/1476-4598-10-89.
• [167] Genomic structure of human OKL38 gene and its differential expression in kidney carcinogenesis.J Biol Chem. 2004 Jan 2;279(1):743-54. doi: 10.1074/jbc.M308668200. Epub 2003 Oct 21.
• [168] PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.Cell Rep. 2018 Feb 27;22(9):2469-2481. doi: 10.1016/j.celrep.2018.02.028.
• [169] Bioplasmonic paper-based assay for perilipin-2 non-invasively detects renal cancer.Kidney Int. 2019 Dec;96(6):1417-1421. doi: 10.1016/j.kint.2019.08.020. Epub 2019 Sep 3.
• [170] Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.Nature. 2016 Feb 25;530(7591):490-4. doi: 10.1038/nature16982. Epub 2016 Feb 15.
• [171] RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA.Cell Cycle. 2016 Nov 16;15(22):3094-3104. doi: 10.1080/15384101.2016.1235103. Epub 2016 Oct 21.
• [172] Gene expression and protein array studies of folliculin-regulated pathways.Anticancer Res. 2012 Nov;32(11):4663-70.
• [173] Rap GTPase Interactor: A Potential Marker for Cancer Prognosis Following Kidney Transplantation.Front Oncol. 2019 Aug 7;9:737. doi: 10.3389/fonc.2019.00737. eCollection 2019.
• [174] Ras regulates SCF(-TrCP) protein activity and specificity via its effector protein NORE1A.J Biol Chem. 2014 Nov 7;289(45):31102-10. doi: 10.1074/jbc.M114.594283. Epub 2014 Sep 12.
• [175] High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma.Eur J Surg Oncol. 2013 Jan;39(1):100-6. doi: 10.1016/j.ejso.2012.10.004. Epub 2012 Oct 24.
• [176] Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.Oncotarget. 2015 Jul 20;6(20):17895-910. doi: 10.18632/oncotarget.4963.
• [177] Knockdown of ribosomal protein S15A inhibits human kidney cancer cell growth invitro and invivo.Mol Med Rep. 2019 Feb;19(2):1117-1127. doi: 10.3892/mmr.2018.9751. Epub 2018 Dec 12.
• [178] Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer.Clin Cancer Res. 2017 Jul 1;23(13):3428-3441. doi: 10.1158/1078-0432.CCR-16-2020. Epub 2016 Nov 22.
• [179] Identification and expression of a sialyltransferase responsible for the synthesis of disialylgalactosylgloboside in normal and malignant kidney cells: downregulation of ST6GalNAc VI in renal cancers.Biochem J. 2007 Mar 15;402(3):459-70. doi: 10.1042/BJ20061118.
• [180] Quantification of C13orf19/P38IP mRNA expression by quantitative real-time PCR in patients with urological malignancies.Cancer Lett. 2005 Jul 28;225(2):253-60. doi: 10.1016/j.canlet.2004.10.037. Epub 2004 Dec 9.
• [181] A Hypoxia-Inducible HIF1-GAL3ST1-Sulfatide Axis Enhances ccRCC Immune Evasion via Increased Tumor Cell-Platelet Binding.Mol Cancer Res. 2019 Nov;17(11):2306-2317. doi: 10.1158/1541-7786.MCR-19-0461. Epub 2019 Aug 19.
• [182] Renal cancer: molecular mechanisms and newer therapeutic options.Curr Opin Nephrol Hypertens. 2002 Jan;11(1):37-42. doi: 10.1097/00041552-200201000-00006.
• [183] Fluorescence in situ hybridization analysis on cytologic smears: An accurate and efficient method in the diagnosis of melanotic Xp11 translocation renal cancer.Diagn Cytopathol. 2018 Sep;46(9):786-789. doi: 10.1002/dc.23961. Epub 2018 May 3.
• [184] Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin.Cell Death Dis. 2019 Dec 4;10(12):919. doi: 10.1038/s41419-019-2088-x.
• [185] Loss of TOP3B leads to increased R-loop formation and genome instability.Open Biol. 2019 Dec;9(12):190222. doi: 10.1098/rsob.190222. Epub 2019 Dec 4.
• [186] The significance of TRIP11 and T3 signalling pathway in renal cancer progression and survival of patients.Endokrynol Pol. 2017;68(6):631-641. doi: 10.5603/EP.a2017.0052. Epub 2017 Oct 12.
• [187] TRC8 suppresses tumorigenesis through targeting heme oxygenase-1 for ubiquitination and degradation.Oncogene. 2013 May 2;32(18):2325-34. doi: 10.1038/onc.2012.244. Epub 2012 Jun 11.
• [188] Tumor Suppressor Function of the SEMA3B Gene in Human Lung and Renal Cancers.PLoS One. 2015 May 11;10(5):e0123369. doi: 10.1371/journal.pone.0123369. eCollection 2015.
• [189] Design, synthesis and evaluation of novel sulfonamides as potential anticancer agents.Comput Biol Chem. 2018 Jun;74:294-303. doi: 10.1016/j.compbiolchem.2018.04.006. Epub 2018 Apr 10.
• [190] Heterozygous Tsc2 (Tsc2+/-) mouse model to study induced renal cancer in response to ionizing radiation at low doses.Carcinogenesis. 2019 Jul 6;40(6):782-790. doi: 10.1093/carcin/bgy172.